Partial pulmonary sympathetic denervation by thoracoscopic D2–D3 sympathicolysis for essential hyperhidrosis: effect on the pulmonary diffusion capacity  by Noppen, M.M.P. & Vincken, W.G.
RESPIRATORY MEDICINE (1997) 91, 537-545 
Partial pulmonary sympathetic denervation by 
thoracoscopic D%D3 sympathicolysis for essential 
hyperhidrosis: effect on the pulmonary diffusion 
capacity 
M. M. P. NOPPEN AND W. G. VINCKEN 
Respivafoy Division, Academic Hospital, AZ- VUB, Univevsify of Bmssels, Brussels, Belgium 
In patients with essential hyperhidrosis (EH), a pathological condition characterized by increased 
activity of the upper dorsal sympathetic ganglia D,D,, anatomical interruption at the D2-D, level by 
thoracoscopic sympathicolysis (TS) is a safe and effective treatment. The Dz and D, ganglia, however, 
are also in the pathway of sympathetic lung innervation, which may influence the pulmonary diffusion 
capacity for carbon monoxide (expressed as transfer factor for CO:RCO, and as transfer coefficient 
for COXCO). 
We therefore studied the effect of TS on TLC0 and KC0 in 50 EH patients: compared with 
pre-operative values, both RCO ( - 6.7%, P<O.OOl) and KC0 ( - 4.2%, P=O.O02) were significantly 
decreased at 6 weeks after bilateral TS, an effect which was independent of the smoking status of the 
patients. In order to explain this phenomenon, the following pharmacological interventions were studied: 
(1) oral Pi+,-adrenoreceptor blockade with propranolol caused a comparable decrease of TLC0 
( - 6.3%) and KC0 ( - 7.5%) in matched normal subjects, but had no effect on TLC0 and KC0 in EH 
patients prior to TS; and (2) subsequent inhalation of the &-adrenoreceptor agonist salbutamol in a 
dosage suspected to cause alveolar P-receptor stimulation had no effect on TLC0 and KCO, neither in 
the normal subjects, nor in EH patients (before and after TS). 
Although the exact mechanism of the TS-induced decrease in RCO and KC0 remains speculative, 
these findings suggest that they may be related to a pi-adrenoreceptor-mediated change in pulmonary 
capillary membrane permeability, although TS-induced changes in pulmonary blood flow or an interplay 
of both mechanisms cannot be excluded. 
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Introduction 
Thoracoscopic sympathicolysis (TS) at the level of the 
upper dorsal sympathetic chain ganglia D,-D, is a 
safe and efficient treatment of essential hyperhidrosis 
(EH) refractory to conventional medical treatment 
(1,2). The D,-D, ganglia are also in the pathway of 
the sympathetic innervation of the lungs and heart. 
Therefore, TS at the D,-D, level may be expected 
to cause a (partial) sympathetic denervation of the 
central thoracic organs. 
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Thoracoscopic sympathicolysis indeed influences 
cardiac autonomic function comparably with the 
effects of a (partial) p-receptor blockade; an asymp- 
tomatic but statistically significant decrease in heart 
rate at rest and at maximal exercise, as well as a 
decrease in diastolic blood pressure response to the 
handgrip test (3,4). Although the sympathetic inner- 
vation of the lungs is sparse, and probably of no 
functional importance in normal humans (25), TS 
does affect pulmonary function tests (PFT); we have 
observed an asymptomatic but significant decrease in 
forced expiratory volume in 1 s (FEV,) ( - 3%) and 
total lung capacity (TLC) (- 2.8%) and an increase 
in airway resistance (RAW) (+30%) (5). After 
correction of these parameters for the small drop in 
lung volume [FEV,/forced vital capacity (FVC), 
specific airway resistance (SRAW), specific airway 
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conductance (SGAW), significant changes disappeared. 
The above-mentioned PFT changes could therefore 
be attributed to a small postoperative decrease in 
lung volume, probably secondary to the thoracoscopic 
procedure itself. The only other parameter that consist- 
ently and significantly decreased after TS, and dis- 
proportionately to the changes in lung volume, was 
forced expiratory flow after exhalation of 75% of the 
vital capacity (FEF,,) (- 7.8%). It was therefore con- 
cluded that D,-D, sympathetic denervation may be 
responsible for a decrease in maximal expiratory flow 
at low lung volumes, suggesting that, at least in EH 
patients, small airway bronchomotor tone is influenced 
by sympathetic innervation (5). Relatively little is 
known about the influence of the autonomic pulmo- 
nary innervation on the pulmonary diffusion capacity 
for carbon monoxide (nC0 and KCO). Autonomic 
factors may influence TLC0 and KC0 by alternating 
pulmonary blood flow and/or ventilation-perfusion 
relationships (alterations in airflow distribution) 
and/or pulmonary vascular permeability (6). In order 
to clarify the effects of the sympathetic innervation on 
the pulmonary diffusion capacity for carbon mon- 
oxide, RCO and KC0 were studied in 50 consecutive 
patients with EH, before and after TS. 
In order to examine the mechanisms underlying the 
observed changes in RCO and KC0 after TS, fur- 
ther studies were performed on other EH patients and 
on normal subjects using autonomic modulation with 
an oral non-selective P-adrenoreceptor blocker (pro- 
pranolol), and an inhaled &-adrenoreceptor agonist 
(salbutamol). Pharmacological p1 +,-adrenoreceptor 
blockade with propranolol was used to create a 
‘pharmacological sympathectomy’, in the assumption 
that the functional sympathetic innervation of 
the lung-when actually present-is mediated via 
/3-adrenoreceptors. 
Inhaled salbutamol was used for two reasons. 
First, via its P,-adrenoreceptor stimulation effects on 
airway smooth muscle receptors, the role of airway 
diameter changes in the changes in 7LCO and 
KC0 (7) could be studied. Second, salbutamol was 
inhaled via a spacer device (Volumatic@) and at a 
dosage of 4OOpg; under these conditions, alveolar 
P-adrenoreceptor stimulation almost certainly occurs 
(S-11), enabling the study of the role of alveolar 
P-adrenoreceptor stimulation on the observed effects 
of TS and propranolol on TLC0 and KCO. 
Materials and Methods 
SUBJECTS 
Fifty consecutive patients with EH (15 men, 35 
women, mean age 28.4 f 8.2 years, range 13-52 
years) underwent TS for the treatment of severe 
refractory EH (group A). A detailed medical history, 
with special emphasis on respiratory or cardiac dis- 
ease, and a complete physical examination were per- 
formed 1-2 weeks before TS. Three patients had a 
history of atopic asthma (6%), but were currently free 
of symptoms and took no medication; 11 patients 
were smokers. All patients gave informed consent, 
and all tests were performed during routine pre- 
operative screening. Three patients were lost for 
follow-up; results are therefore calculated on the 
remaining 47 patients. 
In view of the observed effects of TS on TLC0 and 
KC0 in group A patients, other groups of EH 
patients and normal subjects were studied: 10 other 
consecutive non-smoking EH patients referred for TS 
[two men, eight women, mean age 27.7 i IO.2 years, 
range 16-49 years (group B)]; nine other consecutive 
non-smoking EH patients referred for TS [five men, 
four women, mean age 28.6 f 13.1 years, range 15-48 
years (group C)]; and eight healthy non-smoking 
volunteers [two men and six women, mean age 
29.8 f 4.6 years, range 20-37 years]. The group B and 
group C patients and normal subjects took no medi- 
cation, and had no history of cardiac or pulmonary 
disease. 
All patients and normal subjects gave informed 
consent to the various study protocols, which were 
approved by the Medical Ethics Committee of the 
author’s institution. 
PULMONARY FUNCTION TESTS (PFT) 
All smoking patients refrained from smoking for at 
least 12 h before PFT; therefore, carboxyhaemo- 
globin levels were not measured. The single breath 
pulmonary diffusion capacity for CO (transfer factor 
for CO or TACO), and transfer coefficient for CO 
(KC0 or RCO/VA,,, where VA,, represents the 
effective alveolar volume) were measured in a Sensor- 
Medics 2200 PFT unit (SensorMedics BV, Bilthoven, 
the Netherlands). The gas mixture was composed of 
0.3% carbon monoxide, 0.3% acetylene, 0.3% meth- 
ane (CH4), 21% oxygen and a balance of nitrogen. It 
was inhaled after a maximal expiration and allowed 
to dilute and diffuse during breath holding at maxi- 
mal inspiration. The gas concentrations and volume 
were continuously analysed during the entire post- 
breath-hold exhalation, enabling calculation of the 
mean gas concentrations over an appropriate expired 
volume interval (this method enables adjustment, 
when necessary, of discard and sample collection 
volumes after performance of the test). In all patients, 
the default discard volume of 750 ml was accepted. 
VA,, was calculated from the corrected dilution of 
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CH, and the inspired volume (VI). Anatomical 
(150 ml) and instrumental (85 ml) dead space were 
subtracted from Vl before VA,, was calculated. The 
single breath estimate of residual volume (RV) was 
defined as VA,, minus VI. VA,, in litres BTPS was 
used to calculate RCO, and KC0 was calculated as 
RCONA,,. Breath-holding was preset to 10 s’. &ae- 
moglobin concentrations were previously measured in 
10 other patients before and 6 weeks after TS; since 
no changes were observed, no systematic haemo- 
globin concentrations were determined. The subjects 
were studied at 50 m above sea level. Reference values 
were those of the ECSC (12). RCO and KC0 
measurements were performed at the end of a com- 
plete PFT study, including spirometry and flow- 
volume loops on the same 2200 SensorMedics unit, 
and airway resistance, airway conductance 
and pulmonary volume measurements in a constant 
volume bodyplethysmograph (SensorMedics 6200 
Autobox). The latter data have been analysed in a 
previous paper (6) and will not be used here, except 
for the TLC. 
THORACOSCOPIC SYMPATHICOLYSIS 
Bilateral TS was performed as previously described 
G-4). 
Study Design 
STUDY OF THE EFFECTS OF TS ON TLCO AND 
KC0 IN 47 EH PATIENTS (GROUP A) 
Pulmonary function tests including measurement of 
TLC0 and KC0 (expressed in absolute values and 
in percent predicted) were performed 1 day before 
and 6 weeks after TS, in similar study conditions. 
In order to examine the possible role of smoking 
history on test results, PFT data were also separ- 
ately analysed for smoking and non-smoking EH 
patients. 
STUDY OF THE EFFECTS OF ORAL 
p-ADREN~RECEPT~R BLOCKADE 0~ Taco 
AND KC0 IN GROUP B EH PATIENTS, AND IN 
NORMAL SUBJECTS. COMPARISON WITH THE 
EFFECTS OF SUBSEQUENT TS (GROUP B) AND 
OF SUBSEQUENT INHALED SALBUTAMOL 
(NORMAL SUBJECTS) 
Baseline RCO and KC0 were determined in 10 
group B patients 2 weeks before TS; thereafter 40 mg 
propranolol (Inderal@) was administered t.i.d. for 
2 consecutive days, and on the morning of the 
third day. On the morning of the third day, PFT 
were repeated. Finally, 6 weeks after TS, PFT were 
again repeated. The effects of oral P-adrenoreceptor 
blockade and of TS on TLC0 and KC0 were 
compared. 
Baseline TLC0 and KC0 were also determined in 
eight healthy subjects. Thereafter, propranolol (dos- 
age and scheme, see above) was administered and 
PFT were repeated. In this group, inhaled salbutamol 
was then administered [40O,~g via metered-dose 
inhaler (MDI) with spacer], and PFT were repeated 
15 min later. In this group, the effects of oral pro- 
pranolol and of subsequent inhaled salbutamol on 
RCO and KC0 were assessed. 
STUDY OF THE EFFECTS OF SALBUTAMOL ON 
TLCO AND KC0 IN GROUP C EH PATIENTS, 
BEFORE AND AFTER TS 
Baseline PFT were performed 2 weeks before TS 
in group C patients, followed by inhalation of sal- 
butamol (Ventolin@, 400,~g via MD1 with spacer). 
Pulmonary function tests were repeated after 15 min. 
Similar tests were performed 6 weeks after TS. 
STATISTICAL ANALYSIS 
Data are expressed as mean values f 1 standard 
deviation (SD). Comparison of baseline age, RCO 
and KCO, and gender ratio between the various study 
groups and normal subject groups was performed 
using one way analysis of variance, and the Chi- 
square analysis of contingency table. The effects of 
TS on RCO, KC0 and TLC in group A patients 
were assessed with the paired t-test; differences in 
baseline PFT data between smokers and non-smokers 
were studied with the unpaired Student’s t-test; and 
the changes in TLC0 and KC0 after TS in smokers 
vs. non-smokers were compared with the unpaired 
Student’s t-test. 
The effects of propranolol on TLC0 and KC0 
within group B patients, and within normal subjects, 
were assessed with the Wilcoxon rank-sum test. The 
magnitude of changes in group B patients vs. normals 
was compared with the Mann-Whitney test. To com- 
pare the effects of TS with the effects of propranolol 
in EH group B patients, the Friedman test was used. 
The same test was used to compare the effects of 
salbutamol with the effects of propranolol in normal 
subjects. The effects of salbutamol on RCO and 
KC0 in group C EH patients before and after TS 
were assessed with the Wilcoxon rank-sum test. 
Significance was accepted at PcO.05 (13). 
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TABLE 1. Patient characteristics and baseline 7X0 and KC0 data 
Group A Group B Group C Normals 
II 47 10 9 8 
Age (years) 28.4 f 8.2 27.7 + 10.2 28.6 z!z 13.1 29.8 f 4.6 
M:F 14133 218 514 216 
TLC0 
(mmol min - ’ kPa) 10.18 f 2.22 10.27 zt 1.98 10.78 f 255 10.78 f 3.44 
(% pred) 103.4 f 14.4 104.1 It 10.2 103.8 f 13.1 101.3 f 16.2 
KC0 
(mm01 min-1 kPa-’ 1-l) 1.83 f 0.25 1.79 zt 0.2 1.83 f 0.24 1.78 + 0.23 
(% pred) 85.8 f 12.3 85.3 k 10.2 85.7 f 13 86.4 & 11.5 
TLC (1) 5.87 f 0.98 5.67 zt 1.96 6.1 f 0.98 6.74 f 1.75 
(% pred) 99.4 f 15 102.3 zt 134 104.6 f 16 106.6 f 13 
Alveolar volume (1) 5.76 f 1.03 5.52 f 1.04 5.9 f 0.9 6.5 zt 1.92 
Results are expressed as mean f SD. There were no significant differences for the various parameters between 
groups (ANOVA), nor between TLC and VA within groups (t-test or Mann-Whitney test). 
M:F, male:female ratio; tiC0, transfer factor for carbon monoxide; KCO, transfer coefficient for carbon 
monoxide; % pred, % predicted; TLC, total lung capacity. 
Results 
Baseline TLC0 and KC0 (in absolute values as well 
as in percent predicted) and patient characteristics 
similar in all study groups. Therefore, baseline 
diffusion capacity for CO can be considered normal 
in all EH patient groups (Table 1). Thoracoscopic 
sympathicolysis successfully relieved hyperhidrosis 
in all EH patients, thereby confirming the ana- 
tomical interruption at the D,-D, level, and thus, the 
partial anatomical sympathetic denervation of the 
lungs. After TS, no patient experienced respiratory 
symptoms. 
STUDY OF THE EFFECTS OF TS ON TLCO AND 
KC0 IN 47 EH PATIENTS (GROUP A) 
As compared with baseline values, TLC0 ( - 6.65%, 
P<O.OOl) and KC0 (-4.21%, P=O.O02) had 
decreased slightly but significantly at 6 weeks after 
TS. Baseline RCO was not significantly different 
in smokers (28.81 f 5.2 ml min - ’ mmHg - ‘) as 
compared with non-smokers (30.59 f 6.6 ml min- ’ 
mmHg- ‘, P>O.O5), whereas baseline KC0 was 
significantly lower in smokers (5.02 f 0.79 vs. 
5.57 f 0.69 ml min - ’ mmHg - ‘, PzO.03). How- 
ever, TS-induced changes in TLC0 ( - 5.01 vs. 
- 7.19%, P>O.O5) and in KC0 (- 4.58 vs. - 3.77%, 
P>O.O5) were similar in smokers and non-smokers 
(Table 2). 
STUDY OF THE EFFECTS OF ORAL 
p-ADRENORECEPTOR BLOCKADE 0~ Taco 
AND KC0 IN GROUP B EH PATIENTS, AND IN 
NORMAL SUBJECTS. COMPARISON WITH THE 
EFFECTS ON TLCO AND KC0 OF SUBSEQUENT 
TS (GROUP B), AND OF SUBSEQUENT 
INHALED SALBUTAMOL (NORMAL SUBJECTS) 
In EH patients, /3-adrenoreceptor blockade by means 
of oral propranolol had no significant effects on 
TLC0 and KCO. In the same patient group, how- 
ever, TLC0 ( - 8.2%) and KC0 ( - 8.2%) had signifi- 
cantly decreased 6 weeks after TS. In normal control 
subjects, oral propranolol produced a significant 
decrease in RCO ( - 6.3%) and in KC0 ( - 7.5%), 
comparable to the effects of TS in EH patients, but in 
contrast with the effects of propranolol on TLC0 and 
KC0 in EH patients before TS. Subsequent inha- 
lation of salbutamol in the normal subjects (who still 
were orally ‘P-receptor blocked’ by propranolol) had 
no effects on TLC0 and KC0 [Table 3(a, b)]. 
STUDY OF THE EFFECTS OF SALBUTAMOL ON 
TLCO AND KC0 IN GROUP C EH PATIENTS 
BEFORE AND AFTER TS 
Inhaled salbutamol had no influence on TLC0 
or KC0 in EH patients, before or after TS. [After 
TS, baseline TLC0 and KC0 values, however, 
had decreased significantly as compared with 
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TABLE 3(a). Effects on nC0 and KC0 of oral propranolol and of subsequent TS in group 
B EH patients 
n= 10 Baseline After propranolol After TS 
TLC0 10.27 f 1.88 9.85 i 1.97 9.34 i 1.75 
(mmol min - ’ kPa - ‘) NS PcO.05 
KC0 1.79 f 0.2 1.73 zt 0.2 1.64 I-t 0.25 
(mmol mini’ kPa-’ 1-l) NS PCO.05 
See Table 2 for legend. 
TABLE 3(b). Effects on 7’1C0 and KC0 of oral propranolol and of subsequent inhaled 
salbutamol in normal subjects 
n=X Baseline After propranolol After salbutamol 
TLC0 10.78 + 3.44 10.0 f 3.42 10.23 i 3.37 
(mm01 min - ’ kPa - ‘) PCO.05 NS 
KC0 1.78 f 0.23 1.64 + 0.12 1.63 f 0.16 
(mm01 min-’ kPa-’ 1-l) PCO.05 NS 
See Table 2 for legend. 
TABLE 4. Effects on TLC0 and KC0 of inhaled salbutamol in group C EH patients before 
and after TS 
n=9 
Before TS 
Baseline Salbutamol 
After TS 
Baseline Salbutamol 
TLC0 10.78 f 2.55 10.79 zt 2.44 9.62 & 2.99* 9.95 f 2.37 
(mmol min - ’ kPa - ‘) NS NS 
KC0 1.83 f 0.24 1.83 i 0.26 1.72 f 0.26” 1.76 f 0.21 
(mmol min- ’ kPa- ’ 1-r) NS NS 
See Table 2 for legend. 
“As compared with baseline before TS. 
pre-operative values, confirming the findings in the 
study of EH patients (group A) (Table 4)]. 
Discussion 
This study shows that partial sympathetic denerva- 
tion of the lungs by means of bilateral thoracoscopic 
D,-D, sympathicolysis in patients with EH produces 
an asymptomatic, but statistically significant decrease 
in the CO diffusion capacity of the lung, expressed as 
TLC0 and KCO. This decrease cannot be attributed 
to the small decrease in TLC which is observed after 
thoracoscopy (5) because the decrease in RCO 
( - 6.7%) is disproportionate to the decrease in TLC 
(- 2.8%), and persists after correction for lung vol- 
ume (KC0 - 4.2% change). Furthermore, although 
an inverse relationship between alveolar volume and 
KC0 has been observed (l&16), this is most pro- 
nounced at volumes below 80% of TLC. Above this 
volume, the relationship is constant (14,17). The 
small but significant drop in RCO and KC0 after 
TS, observed in EH patients, therefore represents a 
real change. 
Is this change due to the act of thoracoscopy in 
itself, or to the sympathetic denervation of the lung? 
To the authors’ knowledge, there are no data on PFT 
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changes (including RCO and KCO) after thoracos- 
copy in patients without lung or pleural diseases. 
However, it seems very unlikely that a minimally 
invasive technique such as thoracoscopy, without any 
intervention on the lung, would permanently influ- 
ence the pulmonary diffusion capacity. Furthermore, 
PFTs were obtained 6 weeks after thoracoscopy, a 
period which was long enough for complete recovery 
from anaesthesia and the sequellae of thoracoscopy 
(chest pain). It is therefore hypothesized that the 
observed changes in TLC0 and KC0 are attributable 
to the partial pulmonary sympathetic denervation, 
rather than to the thoracoscopic intervention. 
The pulmonary diffusion capacity can be influ- 
enced by various factors (6,17), which may be related 
to: (1) changes in the diffusion characteristics of the 
alveolocapillary membrane (Dm); and (2) changes in 
the diffusion characteristics of the red blood cells in 
the capillary bed (QeVc), according to the model of 
Roughton and Forster (18) describing gas transport 
between the alveolar space and the red blood cells by 
the equation: 
l/DL= l/DM+ l/Q*Vc 
where DL is the diffusion capacity of the whole lung. 
Within-subject changes in Dm can occur because 
of changes in alveolar surface (alveolar volume) or 
changes in alveolocapillary membrane thickness. The 
observed change in TLC, and therefore alveolar vol- 
ume [in healthy lungs, alveolar volume is similar to 
TLC (19)], however, cannot explain the changes in 
TLC0 and KC0 (see above). Structural changes 
in the diffusion membrane, as can be seen, e.g. in 
interstitial lung diseases, are highly unlikely to occur 
after TS. Thickness and composition of the diffusion 
membrane could, however, theoretically be changed 
after TS, e.g. by an increase in interstitial fluid 
content due to increased vascular permeability; the 
latter may be influenced by P-adrenoreceptor activity 
in the alveolar wall. Indeed, autoradiographic label- 
ling studies have revealed a dense labelling of 
/3-adrenoreceptors in the alveolar walls accounting 
for more than 90% of total P-receptors in human 
lung. Approximately 30% of these receptors are of 
the &-subtype, and 70% of the /&-subtype (20). 
The function of these abundantly present alveolar 
P-adrenoreceptors is unclear but may be involved 
in the regulation of capillary permeability (20) e.g. in 
the rat, P-receptor stimulation causes a decrease 
in capillary permeability (21). Furthermore, the pres- 
ence of as many fir-receptors is surprising since no 
sympathetic innervation of the alveolar walls has 
been demonstrated (22), which defies the idea that all 
/?,-adrenoreceptors are ‘innervated’ (20). 
The TS-induced decrease in RCO and KC0 hypo- 
thetically may be explained by a TS-induced decrease 
of P-receptor activity in the lung, thereby increasing 
pulmonary vascular leakiness and interstitial fluid 
content. Since we have previously shown (30) that 
TS is followed by a significant decrease in plasma 
norepinephrine &-receptor mediator) whereas 
plasma epinephrine (&receptor mediator) remains 
unchanged, the TS-induced effect on alveolocapillary 
permeability is probably mediated via a decrease in 
&-receptor activity. 
This mechanism is compatible with the observed 
decrease in RCO and in KC0 in normal controls 
after P-receptor blockade by means of propranolol, 
which is comparable to the decrease in TLC0 and 
KC0 after TS in EH patients. However, in the 
presence of an intact sympathetic innervation (prior 
to TS), oral propranolol had no effects on TLC0 and 
KC0 in EH patients. This may be explained by 
non-adrenergic effects of sympathetic pulmonary 
innervation or by a competition effect; the hypersym- 
pathicotony in EH (3,4) may have ‘protected’ against 
propranolol. In EH patients, higher doses of pro- 
pranolol are perhaps needed to achieve complete 
P-receptor blockade, although heart rate had 
decreased significantly in the EH patients and in 
the normal patients. The observation that inhaled 
salbutamol, a specific &adrenoreceptor agonist, 
has no effect on RCO and KC0 in EH patients 
(before or after TS) supports our hypothesis that 
the TS-associated decrease in RCO and KC0 is 
mediated through a pi- and not a &adrenoreceptor 
related mechanism. However, another explanation 
for the lack of effect of inhaled salbutamol may be 
that its dosage may have been too small to counter- 
act the P-receptor blocking action of propranolol. 
Further studies using higher inhaled dosages, or 
intravenous administration, are necessary to confirm 
or refute this hypothesis. 
The Q*Vc factor basically consists of pulmonary 
capillary blood volume, blood haemoglobin concen- 
tration and CO back pressure (6,17). Changes in 
pulmonary blood flow (independently of possibly 
associated changes in vascular permeability, see 
above) can indeed alter the pulmonary diffusion 
capacity (6). However, with respect to the RCO as a 
measure related to the size of the capillary bed, it is of 
interest that a doubling of pulmonary blood flow 
does not appreciably alter TLC0 (23,24). Neverthe- 
less, TLC0 increases in parallel with an increase in 
pulmonary capillary blood flow provided that mean 
pulmonary artery pressure (PPA) is also allowed to 
increase (25). Parallel to changes in PPA or pulmo- 
nary vascular resistance, infusion of atropine causes 
a decrease in RCO, and norepinephrine and iso- 
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proterenol infusion induce an increase in TLC0 of 
about lo-20% (26). In dogs, a- and p-adrenoreceptor 
blockade resulted in pulmonary vasodilation and 
vasoconstriction, respectively, whereas cholinergic 
blockade causes pulmonary vasodilation at higher 
levels of blood flow (27). 
According to these data, and irrespective of 
changes in vascular permeability, TS-associated 
decreases in RCO and KC0 may therefore also be 
mediated through TS-induced changes in pulmonary 
artery pressure and/or pulmonary blood flow. 
Although plausible, this mechanism would seem 
quantitatively less important than the ‘vascular per- 
meability hypothesis’, because there are much less 
/&adrenoreceptors present at the smooth muscle 
of vessels, and because they are entirely of the 
&receptor subtype (20). Since TS is associated with a 
decrease in norepinephrine (‘&-mediator’) and not 
in epinephrine (‘&mediator’) (30), and because an 
inhaled &adrenoreceptor agonist (salbutamol) in a 
dose sufficient for ‘systemic’ effects had no effect on 
TLC0 and KCO, this mechanism is less probable, 
although it cannot be excluded. 
A decrease in blood haemoglobin concentration 
after TS could also explain the observed decrease in 
TLC0 and KC0 (6). However, TS is a completely 
bloodless intervention, and blood haemoglobin con- 
centrations in 10 EH patients before and 6 weeks 
after TS were similar (14.8 f 1.3 vs. 14.7 & 1.4 g dll ‘, 
BO.05). 
The serial measurements of 7X0 and KC0 in the 
pharmacological tests theoretically also could have 
been influenced by an increase in back pressure of 
capillary carbon monoxide, thereby reducing the 
available binding sites at the haemoglobin molecule 
(28). However, up to nine serial measurements of 
RCO and KC0 with lo-min intervals in five healthy 
volunteers did not cause significant changes in RCO 
and KC0 (data not shown). 
Finally, the pulmonary diffusion capacity may be 
influenced by associated changes in (expiratory) flow 
rates (7). Airflow obstruction indeed has been shown 
to overestimate the single breath carbon monoxide 
diffusion capacity (29). However, since TS was shown 
to induce a decrease in FEV, and in FEF,, (5), TLC0 
and KC0 would be expected to increase after TS. 
Furthermore, inhaled salbutamol, an agent predomi- 
nantly acting on airway diameter and thus flow rates, 
did not influence the RCO or KCO. 
In conclusion, upper dorsal thoracoscopic sym- 
pathicolysis performed for the treatment of EH, 
causes an asymptomatic but statistically significant 
decrease in TLC0 and KCO, the exact mechanism 
of which remains unclear. Pharmacological modula- 
tion studies suggest that P,-adrenoceptor-mediated 
changes in pulmonary capillary membrane per- 
meability may be responsible, although changes in 
pulmonary blood flow and/or pressure also may be 
involved. 
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